DHRHealthcare · Diagnostics & ResearchThe 25 Wall Street analysts covering Danaher Corp. hold a median 12-month price target of $249 — +8.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 15 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Danaher Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (94): The share price has been relatively steady.
Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.5% from it.
Of the 20 most recent actions, 6 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $220 → $240 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $236 → $255 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $230 → $255 |
| 5 Oct 2026 | RBC Capital | Maintains | Outperform | $215 → $250 |
| 5 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $200 → $250 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 22 July 2026 | Guggenheim | Maintains | Buy | — |
| 22 July 2026 | Guggenheim | Maintains | Buy | $235 → $200 |
| 22 July 2026 | RBC Capital | Maintains | Outperform | — |
| 22 July 2026 | RBC Capital | Maintains | Outperform | $200 → $215 |
| 22 July 2026 | Stifel | Maintains | Buy | — |
| 22 July 2026 | Stifel | Maintains | Buy | $260 → $220 |
| 22 July 2026 | TD Cowen | Maintains | Buy | $240 → $236 |
| 22 July 2026 | TD Cowen | Maintains | Buy | — |
| 22 July 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 22 July 2026 | Wells Fargo | Maintains | Equal-Weight | $212 → $195 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $232 → $230 |
| 11 June 2026 | Piper Sandler | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DHR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Danaher Corp. returned +9.4% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 19% of US stocks
Cheaper than 30% of US stocks
Cheaper than 12% of US stocks
Higher than 40% of US stocks
Higher than 76% of US stocks
Higher than 71% of US stocks
Higher than 79% of US stocks
Higher than 79% of US stocks
Higher than 58% of US stocks
Higher than 71% of US stocks
Higher than 67% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Danaher Corp. has a market value of $162.7B and an enterprise value of $186.3B.
Revenue in the twelve months to 30 June 2026: $25.1B. The latest quarter grew 5.5% year on year.
Net income over the same four quarters: $4.0B, a 15.9% net margin.
Diluted earnings per share, trailing twelve months: $5.63.
Free cash flow in the twelve months to 30 June 2026: $5.5B, after $1.1B of capital spending.
Danaher Corp. spent $2.9B on share buybacks and $964.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 40.9×; forward P/E: 24.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.69%, paying out 26% of earnings.
Danaher Corp. employs 58,000 people — $433K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Danaher Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Danaher is due to report Q3 results on Oct. 21. Growth in Biotechnology, Diagnostics and Life Sciences is expected to support revenue, while rising costs and currency headwinds are expected to weigh on earnings.
Why it matters — DHR watchers may track how these growth drivers and cost and currency pressures shape the quarterly results.
Zacks Investment Research previews Danaher’s expected performance for the quarter ended September 2026, focusing on key metrics beyond Wall Street’s standard revenue and earnings estimates.
Why it matters — The metrics provide DHR watchers additional context for assessing expectations for the upcoming quarter.
Zacks Investment Research highlights its Earnings ESP as a tool for identifying potential earnings surprises and says investors should take advantage of it now. The headline frames two medical stocks as potential earnings beaters, but the excerpt does not identify them.
Why it matters — The excerpt provides no specific information about Danaher, so DHR watchers cannot determine whether it is one of the stocks discussed.
Zacks Investment Research says Danaher has a history of earnings surprises and currently has two key ingredients it views as supporting the possibility of a beat in its next quarterly report.
Why it matters — DHR watchers may note the article’s positive assessment of factors related to the upcoming earnings report.
Zacks Investment Research says Danaher has two key ingredients associated with a likely earnings beat in its upcoming report and outlines key expectations.
Why it matters — DHR watchers may find the earnings-beat setup and expectations relevant ahead of the upcoming report.
The 25 Wall Street analysts covering Danaher Corp. have a median 12-month price target of $249, with estimates ranging from $200 to $310. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 25 analysts covering Danaher Corp., 22 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Danaher Corp. 83 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, Danaher Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (94 of 100).
No one can know that. What the data says: the median 12-month target from 25 analysts implies +8.5% from the last close, and Ticker Nerd's factor model ranks Danaher Corp. 83 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Danaher Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $310 over the next 12 months.
Danaher Corp. returned +9.4% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics.
The most recent item we track (Zacks Investment Research, 16 Oct 2026): "Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?". Danaher is due to report Q3 results on Oct. 21. Growth in Biotechnology, Diagnostics and Life Sciences is expected to support revenue, while rising costs and currency headwinds are expected to weigh on earnings.
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. Its current business is organized around Biotechnology, Life Sciences, and Diagnostics, with offerings that support areas such as biologics manufacturing, molecular and clinical diagnostics, genomics, and analytical instrumentation. Danaher serves customers across healthcare, research, and industrial settings, helping laboratories and life sciences organizations improve efficiency, precision, and productivity. Headquartered in Washington, D.C., Danaher operates through a portfolio of specialized operating companies that provide products and solutions for scientific discovery, disease detection, and the production of biologic therapies.
CEO Ms. Julie Sawyer Montgomery · 58,000 employees · United States · https://www.danaher.com
